Wednesday September 23, 2020

PAC will probe new HSE pharma deal costs

Probe comes amid concerns around the purported savings attached to the agreement

Susan Mitchell

Deputy Editor and Health Editor

@susmitchellsbp
7th August, 2016
Public Accounts Committee chairman Sean Fleming

Public Accounts Committee chairman Sean Fleming intends to probe the recent drug pricing deal amid concerns around the purported savings attached to the agreement.

Fleming said he was troubled by the major variation in the savings claimed by the only two parties to the multibillion euro deal that was announced last month.

“There is obviously a huge difference,” Fleming said.

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Related Stories

Large public capital projects could be run through an “independent panel of international experts” as part of public spending reforms, according to the Department of Public Expenditure

Daniel Murray | 10 months ago

The contract covers the supply of office stationery to a range of government bodies and agencies, including the HSE, universities, hospitals, councils and schools

Michael Brennan | 10 months ago

Party would launch the ‘largest public house building programme that Ireland has ever seen’ and a national health service

Aiden Corkery | 10 months ago